{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:20:41Z","timestamp":1795022441681,"version":"4.10.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"abstract":"<jats:p>\n                    Active surveillance (AS) is an established strategy for managing low-risk prostate cancer (LRPCa), aiming to reduce overtreatment while maintaining oncological safety. This retrospective cohort study included 102 patients diagnosed with LRPCa between 2015 and 2025, managed with serial prostate-specific antigen (PSA) testing, digital rectal examination, multiparametric MRI (mpMRI), and confirmatory biopsies. Transition criteria included Gleason score upgrading, PSA progression, lesion progression on mpMRI, or patient preference. The median follow-up was 16 months (range: 6\u2013123), while the estimated median surveillance duration was 36 months (95% confidence interval: 30\u201342). Retention rates at 2 and 5 years were 72% and 50%, respectively. A total of 35.3% (36\/102) of patients discontinued AS, most frequently due to patient preference (61.1%), followed by PSA progression (25.0%) and histopathological upgrading (13.9%). Only 25.5% (26\/102) of patients underwent confirmatory biopsy during follow-up, reflecting suboptimal adherence that may have contributed to an underestimation of true pathological progression. Multivariate analysis revealed that higher final PSA levels (odds ratio [OR]: 1.559,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.001), abnormal digital rectal examination findings (OR: 11.079,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), and Prostate Imaging-Reporting and Data System 4 to 5 lesions on mpMRI (OR: 5.482,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) were independently associated with transition to definitive treatment. These findings suggest that AS remains a feasible and effective management strategy for LRPCa, though confirmatory biopsies and structured psychological support are essential to optimize adherence and prevent overtreatment. Future studies should investigate the integration of biomarkers and AI-assisted imaging in refining AS protocols.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045691","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:01:08Z","timestamp":1761332468000},"page":"e45691","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of active surveillance in low-risk prostate cancer: A retrospective cohort study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-6777","authenticated-orcid":false,"given":"Dursun","family":"Baba","sequence":"first","affiliation":[{"name":"Department of Urology, Duzce University, Faculty of Medicine, Duzce, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3063-8545","authenticated-orcid":false,"given":"Melih","family":"Bal\u00e7in","sequence":"additional","affiliation":[{"name":"Department of Urology, Duzce University, Faculty of Medicine, Duzce, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3072-9252","authenticated-orcid":false,"given":"Yusuf","family":"\u015eeno\u011flu","sequence":"additional","affiliation":[{"name":"Department of Urology, Marmara University Faculty of Medicine, \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8051-5802","authenticated-orcid":false,"given":"Ahmet Yildirim","family":"Balik","sequence":"additional","affiliation":[{"name":"Department of Urology, Duzce University, Faculty of Medicine, Duzce, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8319-512X","authenticated-orcid":false,"given":"Ekrem","family":"Ba\u015faran","sequence":"additional","affiliation":[{"name":"Department of Urology, Duzce University, Faculty of Medicine, Duzce, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4556-3475","authenticated-orcid":false,"given":"Arda Ta\u015fkin","family":"Ta\u015fkiran","sequence":"additional","affiliation":[{"name":"Department of Urology, Duzce University, Faculty of Medicine, Duzce, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8817-5769","authenticated-orcid":false,"given":"Mehmet Ali","family":"\u00d6zel","sequence":"additional","affiliation":[{"name":"Department of Radiology, Duzce University Faculty of Medicine, Duzce, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-0661","authenticated-orcid":false,"given":"Muhammet Ali","family":"Kayik\u00e7i","sequence":"additional","affiliation":[{"name":"Department of Urology, Duzce University, Faculty of Medicine, Duzce, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261118","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer.","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"R2-20261118","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R3-20261118","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1515\/cclm-2019-0693","article-title":"Biomarkers for prostate cancer: prostate-specific antigen and beyond.","volume":"58","author":"Duffy","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"R4-20261118","doi-asserted-by":"crossref","first-page":"1491314","DOI":"10.3389\/fonc.2025.1491314","article-title":"Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings.","volume":"15","author":"Aprikian","year":"2025","journal-title":"Front Oncol"},{"key":"R5-20261118","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOU.0000000000000393","article-title":"Active surveillance for low-risk prostate cancer.","volume":"27","author":"Klotz","year":"2017","journal-title":"Curr Opin Urol"},{"key":"R6-20261118","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review.","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"R7-20261118","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2023.12.007","article-title":"Patient-reported Side Effects 1 Year after radical prostatectomy or radiotherapy for prostate cancer: a register-based nationwide study.","volume":"7","author":"Corsini","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"R8-20261118","first-page":"CD006590","article-title":"Radical prostatectomy versus deferred treatment for localised prostate cancer.","volume":"6","author":"Vernooij","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20261118","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00345-021-03622-8","article-title":"Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes.","volume":"40","author":"Walker","year":"2022","journal-title":"World J Urol"},{"key":"R10-20261118","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.euf.2020.01.001","article-title":"When and how should active surveillance for prostate cancer be de-escalated?","volume":"7","author":"Rajwa","year":"2021","journal-title":"Eur Urol Focus"},{"key":"R11-20261118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-med-063014-123902","article-title":"Management of benign prostatic hyperplasia.","volume":"67","author":"Kim","year":"2016","journal-title":"Annu Rev Med"},{"key":"R12-20261118","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.21873\/anticanres.14446","article-title":"Radiotherapy of prostate carcinoma: a comparison of the predictive role of EAU Versus NCCN Risk Stratification Systems.","volume":"40","author":"Buwenge","year":"2020","journal-title":"Anticancer Res"},{"key":"R13-20261118","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","article-title":"Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies?-a systematic diagnostic test accuracy review.","volume":"4","author":"Hettiarachchi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"R14-20261118","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41391-021-00417-1","article-title":"Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level.","volume":"25","author":"Oerther","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R15-20261118","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.euo.2019.05.005","article-title":"Intensity of active surveillance and transition to treatment in men with low-risk prostate cancer.","volume":"3","author":"Olsson","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"R16-20261118","first-page":"72","article-title":"Active surveillance in men with low-risk prostate cancer: current and future challenges.","volume":"1","author":"Han","year":"2013","journal-title":"Am J Clin Exp Urol"},{"key":"R18-20261118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.prnil.2021.11.001","article-title":"Is antibiotic prophylaxis still mandatory for transperineal prostate biopsy? Results of a comparative study.","volume":"10","author":"Pirola","year":"2022","journal-title":"Prostate Int"},{"key":"R19-20261118","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/bco2.406","article-title":"Value of a confirmatory re\u2010biopsy as part of a modern risk stratified cancer surveillance programme for early prostate cancer.","volume":"5","author":"Gabb","year":"2024","journal-title":"BJUI Compass"},{"key":"R20-20261118","doi-asserted-by":"crossref","first-page":"e920252","DOI":"10.12659\/MSM.920252","article-title":"Active surveillance of prostate cancer using multiparametric magnetic resonance imaging: a review of the current role and future perspectives.","volume":"26","author":"Sklinda","year":"2020","journal-title":"Med Sci Monitor"},{"key":"R21-20261118","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/iju.13016","article-title":"Active surveillance for prostate cancer.","volume":"23","author":"Romero-Otero","year":"2016","journal-title":"Int J Urol"},{"key":"R23-20261118","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12894-023-01314-6","article-title":"Active surveillance should be considered for select men with Grade Group 2 prostate cancer.","volume":"23","author":"Pekala","year":"2023","journal-title":"BMC Urol"},{"key":"R25-20261118","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jfma.2024.03.014","article-title":"The factors impacting on Gleason score upgrading in prostate cancer with initial low Gleason scores.","volume":"124","author":"Huang","year":"2025","journal-title":"J Formosan Med Assoc = Taiwan yi zhi"},{"key":"R26-20261118","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A Contemporary prostate cancer grading system: a validated alternative to the gleason score.","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"R27-20261118","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.urology.2019.01.061","article-title":"Contemporary management of incident prostate cancer in large community urology practices in the United States.","volume":"129","author":"Shelton","year":"2019","journal-title":"Urology"},{"key":"R28-20261118","first-page":"57","article-title":"The role of multiparametric MRI and MRI-targeted biopsy in detecting clinically significant prostate cancer in the community setting: a retrospective study.","volume":"22","author":"Schmanke","year":"2020","journal-title":"Rev Urol"},{"key":"R29-20261118","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/pros.24764","article-title":"Natural history of histologically benign PIRADS 4-5 lesions in multiparametric MRI: Real-life experience in an academic center.","volume":"84","author":"Madendere","year":"2024","journal-title":"Prostate"},{"key":"R30-20261118","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on Active Surveillance (ASIST): 2-year postbiopsy follow-up.","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"key":"R31-20261118","first-page":"91","article-title":"an introduction to survival statistics: kaplan-meier analysis.","volume":"7","author":"Dudley","year":"2016","journal-title":"J Adv Practitioner Oncol"},{"key":"R32-20261118","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"R33-20261118","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdv607","article-title":"Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study.","volume":"27","author":"Thomsen","year":"2016","journal-title":"Ann Oncol"},{"key":"R34-20261118","first-page":"859","article-title":"Prognostic role of prostate-specific antigen isoforms and their early kinetics in patients with metastatic castration-resistant prostate cancer receiving new generation androgen receptor targeted agents.","volume":"39","author":"Fiala","year":"2025","journal-title":"In vivo (Athens, Greece)"},{"key":"R35-20261118","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1464-410X.2006.06647.x","article-title":"An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men.","volume":"99","author":"Borden","year":"2007","journal-title":"BJU Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:01:03Z","timestamp":1795021263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":32,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045691","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"2025-03-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}